Close Menu

More articles about Molecular Diagnostics

The test relies on a spermine risk score coupled with a urine test to predict which patients are most likely to have prostate cancer.

RenalytixAI will provide financial support to the University of Utah in the form of sponsored research into kidney disease progression, treatment, and biomarkers.

Total revenues for the period were $154.6 million, down from $195.1 million but beating the consensus Wall Street estimate.

Laboratory staffing and supply shortages limited patient access to cancer screening tests, and the pandemic decreased the development and validation of new tests.

A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.

Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.

The expanded partnership includes a commercial agreement for the ClonoSeq and ImmunoSeq assays, as well as a lab service agreement for the T-Detect COVID test.

The lab will use its phlebotomy network to help Grail with specimen collection for its Galleri multi-cancer early detection blood test, slated to launch this year.

Cue said that US-based K-12 schools, essential businesses, nursing homes, hospitals, and physicians' offices are already using its COVID-19 test. 

The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.

The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.

PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.

Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.

The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.

The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.

TruGenX claims that Thermo Fisher's technical support did not resolve testing issues for months, damaging its business and reputation.

The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.

The researchers at the Royal College of Surgeons Ireland recently received €1.3 million from Wellcome Trust to support the development of the blood-based test.

Pages